174 related articles for article (PubMed ID: 20688947)
1. Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin.
Humphries RM; Kelesidis T; Dien Bard J; Ward KW; Bhattacharya D; Lewinski MA
J Med Microbiol; 2010 Nov; 59(Pt 11):1383-1386. PubMed ID: 20688947
[TBL] [Abstract][Full Text] [Related]
2. High-dose tigecycline and colistin for successful treatment of disseminated carbapenem-resistant Klebsiella pneumoniae infection in a liver transplant recipient.
Dan JM; Mendler MH; Hemming AW; Aslam S
BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25378111
[TBL] [Abstract][Full Text] [Related]
3. NDM-1-producing Klebsiella pneumoniae in Mauritius.
Poirel L; Lascols C; Bernabeu S; Nordmann P
Antimicrob Agents Chemother; 2012 Jan; 56(1):598-9. PubMed ID: 22006002
[No Abstract] [Full Text] [Related]
4. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli.
Docobo-Pérez F; Nordmann P; Domínguez-Herrera J; López-Rojas R; Smani Y; Poirel L; Pachón J
Int J Antimicrob Agents; 2012 Mar; 39(3):251-4. PubMed ID: 22154856
[TBL] [Abstract][Full Text] [Related]
5. Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-β-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis.
Stone NR; Woodford N; Livermore DM; Howard J; Pike R; Mushtaq S; Perry C; Hopkins S
J Antimicrob Chemother; 2011 Nov; 66(11):2677-8. PubMed ID: 21846669
[No Abstract] [Full Text] [Related]
6. Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae.
Tsala M; Vourli S; Daikos GL; Tsakris A; Zerva L; Mouton JW; Meletiadis J
J Antimicrob Chemother; 2017 Jan; 72(1):172-180. PubMed ID: 27650184
[TBL] [Abstract][Full Text] [Related]
7. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Neuner EA; Yeh JY; Hall GS; Sekeres J; Endimiani A; Bonomo RA; Shrestha NK; Fraser TG; van Duin D
Diagn Microbiol Infect Dis; 2011 Apr; 69(4):357-62. PubMed ID: 21396529
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii.
Mutlu Yilmaz E; Sunbul M; Aksoy A; Yilmaz H; Guney AK; Guvenc T
Int J Antimicrob Agents; 2012 Oct; 40(4):332-6. PubMed ID: 22831842
[TBL] [Abstract][Full Text] [Related]
9. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone.
Cobo J; Morosini MI; Pintado V; Tato M; Samaranch N; Baquero F; Cantón R
Diagn Microbiol Infect Dis; 2008 Mar; 60(3):319-22. PubMed ID: 17996417
[TBL] [Abstract][Full Text] [Related]
10. Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination.
Demiraslan H; Dinc G; Ahmed SS; Elmali F; Metan G; Alp E; Doganay M
J Chemother; 2014 Oct; 26(5):276-81. PubMed ID: 24070112
[TBL] [Abstract][Full Text] [Related]
11. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
[TBL] [Abstract][Full Text] [Related]
12. Molecular epidemiology and risk factors for colistin- or tigecycline-resistant carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients during a 7-year period.
Papadimitriou-Olivgeris M; Bartzavali C; Spyropoulou A; Lambropoulou A; Sioulas N; Vamvakopoulou S; Karpetas G; Spiliopoulou I; Vrettos T; Anastassiou ED; Fligou F; Christofidou M; Marangos M
Diagn Microbiol Infect Dis; 2018 Nov; 92(3):235-240. PubMed ID: 30076041
[TBL] [Abstract][Full Text] [Related]
13. Extremely drug-resistant NDM-9-producing ST147
Falcone M; Giordano C; Barnini S; Tiseo G; Leonildi A; Malacarne P; Menichetti F; Carattoli A
Euro Surveill; 2020 Dec; 25(48):. PubMed ID: 33272354
[TBL] [Abstract][Full Text] [Related]
14. Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.
Cheng A; Chuang YC; Sun HY; Sheng WH; Yang CJ; Liao CH; Hsueh PR; Yang JL; Shen NJ; Wang JT; Hung CC; Chen YC; Chang SC
Crit Care Med; 2015 Jun; 43(6):1194-204. PubMed ID: 25793437
[TBL] [Abstract][Full Text] [Related]
15. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
[TBL] [Abstract][Full Text] [Related]
16. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of a disseminated infection with extensively drug-resistant Klebsiella pneumoniae in a liver transplant recipient with a fosfomycin-based multidrug regimen.
Mills JP; Wilck MB; Weikert BC; Porrett PM; Timko D; Alby K; Bonomo RA; Blumberg EA
Transpl Infect Dis; 2016 Oct; 18(5):777-781. PubMed ID: 27458980
[TBL] [Abstract][Full Text] [Related]
18. Ventilator-associated pneumonia caused by colistin-resistant KPC-producing Klebsiella pneumoniae: a case report and literature review.
Viaggi B; Sbrana F; Malacarne P; Tascini C
Respir Investig; 2015 May; 53(3):124-8. PubMed ID: 25951099
[TBL] [Abstract][Full Text] [Related]
19. Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae.
Gaibani P; Lombardo D; Bartoletti M; Ambretti S; Campoli C; Giannella M; Tedeschi S; Conti M; Mancini R; Landini MP; Re MC; Viale P; Lewis RE
Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1925-1931. PubMed ID: 31278562
[TBL] [Abstract][Full Text] [Related]
20. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
